Precision Neuroscience

06/03/2026

For more than two decades, Precision Neuroscience co-founder Dr. Benjamin Rapoport has worked to close the gap between the engineers and scientists building BCI technology and the real-world needs of the people it’s meant to serve — along with their physicians and caregivers.

Today, our BCI tech is designed to help people living with paralysis operate digital devices using only their thoughts, restoring independence and connection for millions. And this is only the beginning. As the technology evolves, it has the potential to expand to more regions of the brain — opening new possibilities for treatment, communication, and scientific discovery.

Learn more here: https://www.precisionneuro.io

06/01/2026

“It’s helpful to think about BCI as a communication tool. Like any communication device, bandwidth matters. What you can do with a 56K modem, maybe chat on AOL, is very different from what you can do with a fiber optic connection, Netflix. It’s the same thing in BCI. Very low electrode count systems are able to enable a click on a computer mouse, maybe a few directions on a cursor. What our system is designed to enable is rich control of sophisticated applications, whether it’s photo editing, or productivity software. Our bar is really to meet and eventually exceed what people who are able bodied do with a computer or a digital device”.

Taken from a new interview with cheddar news, Chris Castellino sits down with Precision Neuroscience CEO & Co-Founder Michael Mager for an inside look at the future of brain-computer interfaces. The feature takes viewers inside the Precision lab, offering a detailed look at how our Layer 7 BCI is designed and built — including an in-depth overview of the Layer 7 array itself and how its 1,024 electrodes work together to capture neural activity at high resolution. The conversation also explores why Precision built our own supply chain from the ground up to manufacture our BCIs — a critical step in scaling this technology for the future.

Watch below.

Precision Neuroscience is implanting human brains with a device thinner than a human hair. Inside the $400B race to connect your brain to a computer.

05/29/2026

Accessibility technology is rapidly becoming everyday tech, and many of the innovations we now rely on started as tools built to expand access — from speech-to-text and predictive typing to eye tracking and captions.

Precision's Layer 7 is designed for real-world human impact and scalability: enabling access to the motor cortex to support people living with paralysis, while advancing toward a whole-brain interface that could transform how we understand and treat neurological conditions.

Learn more about our vision here: https://www.precisionneuro.io/our-vision

05/26/2026

Brain-computer interfaces are no longer science fiction. A recent article from Bloomberg by Ike Swetlitz, Saritha Rai, and Amber Tong explores how quickly the BCI field is evolving.

One of the key themes in the piece is the contrast between brain penetrating and non-penetrating BCIs, along with the different approaches emerging companies are taking to advance the technology. The article also highlights an important milestone for Precision Neuroscience: receiving U.S. Food and Drug Administration (FDA) clearance in 2025 for our minimally invasive, non-penetrating BCI designed to record, monitor, and stimulate brain activity. Precision's technology has already been implanted in more than 85 patients through clinical studies — a strong signal of how rapidly this field is advancing.

Exciting to see the conversation around BCIs shifting from “someday” to real-world impact today.

Startups have developed chips that allow people to control machines with their thoughts. Billionaires are betting these brain-computer interfaces could become everyday consumer tech.

05/22/2026

One year ago, Precision Neuroscience received 510(k) clearance from the U.S. Food and Drug Administration for Layer 7 — our high-resolution cortical electrode array designed to record, monitor, and stimulate electrical activity on the brain’s surface.

At the time, Layer 7 had been tested in just over 35 participants. Today, that number is approaching 90 — made possible through collaborations with leading clinical and research institutions including The Mount Sinai Hospital, Perelman School of Medicine at the University of Pennsylvania, WVU Rockefeller Neuroscience Institute, Beth Israel Deaconess Medical Center, and UChicago Medicine.

Our FDA clearance allows Layer 7 to remain implanted for up to 30 days, enabling commercial use in intraoperative surgical mapping and making it possible to visualize brain activity in real time with unprecedented scale and fidelity. Importantly, this marked the first regulatory clearance granted to a company developing a next-generation wireless brain-computer interface. A meaningful milestone not just for our team, but for the future of real-time neural recording and the people and neurosurgical teams we aim to serve.

05/20/2026

At Precision Neuroscience, we’re building the next generation of brain-computer interface technology — and we’re growing our team. We’re looking for exceptional people across engineering, neuroscience, clinical, product, and operations who are excited to help shape the future of neurotech.

Open positions:
• Senior Mechanical Engineer
• Field Clinical Specialist
• Senior Product Designer
• Vice President of Market Access
• Full-Stack Software Engineer
• Real-Time Software Engineer
• Staff Neuroscientist
• Staff Machine Learning Engineer/Scientist
• Product Manager
• Office Manager
• Equipment Engineer
• Senior Technical Program Manager

If you’re excited by the opportunity to build breakthrough brain-computer interface tech alongside a collaborative team of engineers, neuroscientists and clinicians, we’d love to hear from you. Apply below!

Know someone who’d be a great fit? Tag them below or share this post.

Unlocking the full potential of the brain.

05/18/2026

May is ALS Awareness Month—a time to shine a light on a disease that affects thousands of individuals and families each year. Amyotrophic Lateral Sclerosis (ALS), often known as Lou Gehrig’s disease, is a progressive neurodegenerative condition that impacts the nerve cells responsible for muscle movement. While there is still no cure, continued research, advocacy, and strong community support are helping move us closer to meaningful breakthroughs.

This month is an opportunity to deepen our understanding of ALS and its impact, support organizations working toward treatments and a cure, and elevate the voices of those living with ALS and their caregivers. Learn more about ALS through some of these organizations below:

The ALS Association: https://www.als.org
I AM ALS: https://www.iamals.org
Team Gleason Foundation: https://teamgleason.org/

05/15/2026

At Precision Neuroscience, we’re partnering with leading physicians and institutions to develop Layer 7—with clinical collaboration at the center of everything we do. This model enables continuous performance refinement, rigorous safety validation, and real-world system integration.

To date, Layer 7 has been used in over 85 patients across diverse research and clinical settings. We’re proud to work alongside institutions that are pushing the boundaries of neuroscience and patient care.

Enrollment is now underway for studies in both acute intraoperative and extraoperative settings. Together, we’re accelerating discovery—and bringing the next generation of neurotech closer to patients.

Learn more here: https://www.precisionneuro.io/for-clinicians

05/12/2026

"The goal is to have this technology available as part of the standard of care in a way that really touches people's lives and helps to heal. I think that is a palpable potential reality now."

Precision Neuroscience Co-founder Benjamin Rapoport joined Protocol Labs founder Juan Benet to talk about where BCIs actually stand today and what that means for medicine, AI, and everything in between.

https://www.juanbenetpodcast.com/p/ben-rapoport-treating-paralysis-and?utm_source=notes-share-action&utm_medium=web

Precision Neuroscience’s co-founder and CSO on building Layer 7, a BCI that sits on the surface of the brain, and why neural data is the new genomics.

05/11/2026

Last week at the Milken Institute Global Conference, our Co-Founder and CEO Michael Mager sat down with Bloomberg Markets: The Close to talk about where Precision Neuroscience stands, where the market is going, and what it's going to take for the US to lead.

"There are around 6 million people globally who are completely tetraplegic — that's an addressable market in the hundreds of billions… The promise of brain-computer interfaces goes way beyond paralysis."

https://www.bloomberg.com/news/videos/2026-05-08/precision-neuroscience-ceo-on-medtronic-partnership-video

Precision Neuroscience Co-Founder & CEO Michael Mager discusses the development of a new neurological implant designed to create a communication link with the brain and external computers, as well as the company's partnership with Medtronic. He talks with Romaine Bostick at the Milken Institute Glob...